AMCA
GILD icon

Arthur M. Cohen & Associates’s Gilead Sciences GILD Stock Holding History

Arthur M. Cohen & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$383K Buy
3,030
+110
+4% +$14.5K 0.06% 103
2026
Q1 		$410K Sell
2,920
-110
-4% -$15.4K 0.07% 91
2025
Q4 		$372K Buy
3,030
+520
+21% +$63.2K 0.06% 97
2025
Q3 		$279K Sell
2,510
-1,010
-29% -$115K 0.05% 112
2025
Q2 		$390K Buy
3,520
+1,000
+40% +$106K 0.07% 96
2025
Q1 		$282K Buy
2,520
+10
+0.4% +$1.03K 0.05% 108
2024
Q4 		$232K Hold
2,510
– – 0.04% 127
2024
Q3 		$211K Sell
2,510
-1,150
-31% -$87.8K 0.04% 136
2024
Q2 		$251K Buy
3,660
+925
+34% +$61.7K 0.05% 125
2024
Q1 		$200K Buy
2,735
+110
+4% +$8.46K 0.04% 134
2023
Q4 		$213K Buy
+2,625
New +$204K 0.05% 129

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arthur M. Cohen & Associates's GILD Position: Q2 2026 in Review

Arthur M. Cohen & Associates increased its Gilead Sciences (GILD) stake by 3.8% in Q2 2026, buying an estimated $14.5K and bringing the position to 3,030 shares worth $383K. The position accounts for 0.06% of the portfolio, ranked #103.

Arthur M. Cohen & Associates first reported a position in GILD in Q4 2023 and has held it in 11 quarters since. The position peaked at $410K in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Arthur M. Cohen & Associates held 3,030 shares of Gilead Sciences worth $383K as of Q2 2026.
  • Arthur M. Cohen & Associates bought 110 Gilead Sciences shares in Q2 2026, an estimated $14.5K.
  • Gilead Sciences made up 0.06% of Arthur M. Cohen & Associates's portfolio in Q2 2026, its #103 holding.
  • Arthur M. Cohen & Associates first reported a position in Gilead Sciences in Q4 2023 and has held it in 11 quarters since.
  • Arthur M. Cohen & Associates's Gilead Sciences position peaked at $410K in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Arthur M. Cohen & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.